Form 4: Rocket Pharmaceuticals Director David Southwell Acquires 30,000 Shares of Common Stock

Director David Southwell acquired 30,000 shares of Rocket Pharmaceuticals common stock on June 18, 2025, through the grant of restricted stock units.

Summary

• David Southwell, a director of Rocket Pharmaceuticals, acquired 30,000 shares of common stock on June 18, 2025.
• The acquisition was in the form of restricted stock units (RSUs) that convert to common stock on a one-for-one basis.
• The RSUs were granted at a price of $0.
• The RSUs will vest in full on June 18, 2026.
• Following the transaction, Southwell directly owns 31,660 shares of common stock.
• Southwell indirectly owns 113,124 shares of common stock through The David P. Southwell Irrevocable Trust Dtd 04/14/2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares by a director is generally viewed as a positive sign, but the transaction is part of a standard compensation package.

Positives

• Acquisition of 30,000 shares by a director signals confidence in the company's future.
• The vesting of RSUs in one year incentivizes the director to work towards the company's success.

Future Outlook

The RSUs will vest in full on June 18, 2026, converting to common stock on a one-for-one basis.

Industry Context

This filing reflects insider activity, which is a common occurrence in publicly traded companies. Investors often monitor such filings for signals about management's confidence in the company's prospects.

Stakeholder Impact

• The acquisition of shares by a director can positively influence shareholder sentiment.

Key Dates

Recommendation

Keywords

Rocket Pharmaceuticals, Director, David Southwell, Common Stock, Restricted Stock Units, Acquisition, Beneficial Ownership, SEC Form 4